Comparison of Drugs for Advanced Kidney Cancer Suggests Side Effects Are More Manageable with Newer Option

Add a Comment By Maureen Salamon, BA  |  Thursday, August 22, 2013 An international study led by Memorial Sloan-Kettering found that pazopanib (Votrient ® ) controls cancer as effectively as sunitinib (Sutent ® ) while improving patients’ quality of life. read more

View article:
Comparison of Drugs for Advanced Kidney Cancer Suggests Side Effects Are More Manageable with Newer Option

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share